EF Hutton Initiates Coverage On Viracta Therapeutics with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tony Butler has initiated coverage on Viracta Therapeutics (NASDAQ:VIRX) with a Buy rating and a price target of $10.
July 31, 2023 | 11:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton has initiated coverage on Viracta Therapeutics with a Buy rating and a price target of $10.
The initiation of coverage by EF Hutton with a Buy rating and a price target of $10 indicates a positive outlook for Viracta Therapeutics. This could potentially lead to an increase in investor interest and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100